MEDICLIN AG
ISIN: DE0006595101
WKN: 659510
02 May 2025 12:58PM

EQS-News: MEDICLIN increases group operating result in the first quarter of 2025

MEDICLIN AG · ISIN: DE0006595101 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 2129190

EQS-News: MEDICLIN AG / Key word(s): Quarterly / Interim Statement
MEDICLIN increases group operating result in the first quarter of 2025

02.05.2025 / 12:58 CET/CEST
The issuer is solely responsible for the content of this announcement.


Offenburg, 2 May 2025
MEDICLIN increases group operating result in the first quarter of 2025
                                                                             
  • MEDICLIN increases its group operating result to EUR 5.2 mill.
  • At EUR 184.8 mill., consolidated group sales are at the previous year's level
  • Stable overall capacity utilisation of 85.0%

Offenburg, 02 May 2025: MEDICLIN Aktiengesellschaft (Ticker: MED; WKN 659 510) generated consolidated group sales of EUR 184.8 mill. in the first three months of 2025, on a par with the previous year (3M 2024: EUR 185.4 mill.). The group operating result improved by EUR 1.1 mill. compared to the same period of the previous year, from EUR 4.1 mill. to EUR 5.2 mill. Overall capacity utilisation of 85.0% (3M 2024: 85.0%) underlines a solid first quarter.

 "We have successfully completed the first quarter of the current year. With stable capacity utilisation, stable sales and improved earnings, we are on the way to achieving our annual forecasts," comments Tino Fritz, CFO of MEDICLIN, on the development in the first quarter of 2025.

Developments in the segments

In the post-acute segment, sales totalled EUR 121.8 mill., up EUR 9.1 mill. or 8.1% on the previous year. At 22.0%, the cost of materials ratio was slightly below the previous year's figure of 22.3%. At EUR 26.8 mill., the absolute cost of materials was 6.6% higher than the previous year's figure (3M 2024: EUR 25.1 mill.). Personnel expenses increased by EUR 7.4 mill. or 11.9% to EUR 69.1 mill. compared to the same quarter of the previous year. The personnel expenses ratio rose to 56.7% (3M 2024: 54.8%). The operating result for the post-acute segment of EUR 4.9 mill. corresponds to a decrease of EUR 1.0 mill. compared to the previous year (3M 2024: EUR 5.9 mill.).

Sales in the acute segment totalled EUR 55.3 mill. (3M 2024: EUR 65.7 mill.). At EUR 15.7 mill., the cost of materials was EUR 3.9 mill. or 19.6% lower than in the same quarter of the previous year (3M 2024: EUR 19.6 mill.). The cost of materials ratio fell slightly to 28.4% (3M 2024: 29.8%). Personnel expenses totalled EUR 34.8 mill. and were therefore 12.4% lower than in the first three months of 2024
(3M 2024: EUR 39.7 mill.). The personnel expenses ratio was 62.8% after 60.4% in the same period of the previous year. The decline in sales and expense items in the acute segment is mainly due to the sale of the former MEDICLIN Herzzentrum Coswig. The segment operating result totalled EUR 0.0 mill. after EUR –1.3 mill. in the first quarter of 2024.

Sales in the nursing care segment rose to EUR 6.2 mill. in the first quarter of 2025 (3M 2024: EUR 5.9 mill.), while the segment operating result of EUR –0.1 mill. was just below the same period of the previous year (3M 2024: EUR 0.0 mill.).

In the Service segment, sales increased by EUR 1.4 mill. to EUR 26.1 mill. (3M 2024: EUR 24.7 mill.). At EUR 0.4 mill., the segment operating result was EUR 0.9 mill. higher than in the same period of the previous year (3M 2024: EUR –0.5 mill.).

The interim report as at 31 March 2025 is available from today at www.mediclin.de in German and English.

For more information:

MEDICLIN Aktiengesellschaft
Okenstraße 27
77652 Offenburg
Germany

Investor Relations
Ender Gülcan
Phone +49 781/488-326
ender.guelcan@mediclin.de


www.mediclin.de


About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)
MEDICLIN includes 31 clinics, six care facilities and ten medical care centers. The group has around 8,200 beds/care places and employs around 9,900 people.
In a strong network, MEDICLIN offers the patients integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN ─ a company of the Asklepios Group

 


02.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MEDICLIN AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: ender.guelcan@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2129190

 
End of News EQS News Service

2129190  02.05.2025 CET/CEST

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2019 2020 2021 2022 2023 2024 2025e
Sales1 673,09 659,86 673,14 704,70 730,07 748,75 778,00
EBITDA1,2 93,58 77,50 85,22 90,92 98,73 103,77 115,00
EBITDA-Margin3 13,90 11,75 12,66 12,90 13,52 13,86 14,78
EBIT1,4 22,41 0,15 11,56 19,52 12,72 53,49 63,00
EBIT-Margin5 3,33 0,02 1,72 2,77 1,74 7,14 8,10
Net Profit (Loss)1 9,68 -0,04 1,49 9,72 -10,72 24,91 35,00
Net-Margin6 1,44 -0,01 0,22 1,38 -1,47 3,33 4,50
Cashflow1,7 69,59 118,69 81,97 34,64 78,00 50,57 74,00
Earnings per share8 0,20 -0,19 0,03 0,20 -0,23 0,52 0,74
Dividend per share8 0,05 0,00 0,00 0,00 0,00 0,04 0,04
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: KPMG

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Mediclin
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
659510 DE0006595101 AG 179,55 Mio € 06.12.2000 Kaufen 8FW9FWGV+63
* * *
PE 2026e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
5,82 17,70 0,33 17,10 0,73 2,23 0,24
Dividends
Dividend '2023
in €
Dividend '2024
in €
Dividend '2025e
in €
Div.-Yield '2025e
in %
0,00 0,04 0,04 1,06%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
28.06.2026 04.05.2026 30.07.2026 04.11.2025 27.03.2026
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+0,00%
3,78 €
ATH 15,02 €
+12,80% +22,77% +56,20% +52,42% -65,64%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2025          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2025 by Gereon Kruse #BGFL